Insights

New Jersey Statutory Update – Part I

For more information about this blog post, please contact Ryan L. O’Neill, Labinot Alexander Berlajolli, or Jessica T. Osterlof or Samantha T....

Second Temporary Extension of COVID-19 Telemedicine Flexibilities for Prescription of Controlled Medications

For more information about this blog post, please contact Ryan L. O’Neill, Labinot Alexander Berlajolli, or Jessica T. Osterlof or Samantha T....

CMS’ Proposed Drug Pricing Transparency Rule Impacting PBMs and Other PBM Updates

For more information about this blog post, please contact Ryan L. O’Neill, Labinot Alexander Berlajolli, or Jessica T. Osterlof or Samantha T....

Third Circuit Ruling Highlights Burden With Statistical Sampling

For more information about this blog post, please contact Ryan L. O’Neill, Labinot Alexander Berlajolli, or Jessica T. Osterlof or...

New Final DEA and CMS FY 2024 Payment Rules

For more information about this blog post, please contact Ryan L. O’Neill, Labinot Alexander Berlajolli or Jessica T. Osterlof. DEA Finalizes...

New Jersey Regulatory Update, Part IV

For more information about this blog post, please contact Ryan L. O’Neill, Labinot Alexander Berlajolli or Jessica T. Osterlof. Part...

New Jersey Regulatory Update, Part III

For more information about this blog post, please contact Ryan L. O’Neill, Labinot Alexander Berlajolli or Jessica T. Osterlof. Part...

New Jersey Regulatory Update, Part II

For more information about this blog post, please contact Ryan L. O’Neill, Labinot Alexander Berlajolli or Jessica T. Osterlof. Part...

New Jersey Regulatory Update, Part I

For more information about this blog post, please contact Ryan L. O’Neill, Labinot Alexander Berlajolli or Jessica T. Osterlof. As...